NEURONTIN CAPSULE

Țară: Canada

Limbă: engleză

Sursă: Health Canada

Cumpara asta acum

Ingredient activ:

GABAPENTIN

Disponibil de la:

BGP PHARMA ULC

Codul ATC:

N02BF01

INN (nume internaţional):

GABAPENTIN

Dozare:

100MG

Forma farmaceutică:

CAPSULE

Compoziție:

GABAPENTIN 100MG

Calea de administrare:

ORAL

Unități în pachet:

100

Tip de prescriptie medicala:

Prescription

Zonă Terapeutică:

MISCELLANEOUS ANTICONVULSANTS

Rezumat produs:

Active ingredient group (AIG) number: 0125929001; AHFS:

Statutul autorizaţiei:

APPROVED

Data de autorizare:

2001-01-05

Caracteristicilor produsului

                                _NEURONTIN (gabapentin) _
_Page 1 of 38_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NEURONTIN®
Gabapentin Capsules
Capsules, 100 mg, 300 mg and 400 mg, oral
Gabapentin Tablets
Tablets, 600 mg and 800 mg, oral
Antiepileptic Agent
BGP Pharma ULC
85 Advance Road
Etobicoke (Ontario)
Canada M8Z 2S6
Date of Initial Approval:
MAY 05, 2023
Date of Revision:
OCTOBER 16, 2023
Submission Control No: 275525
®
Viatris Specialty LLC
BGP Pharma ULC, a Viatris company, Licensee
© BGP Pharma ULC, 2023
_ _
_NEURONTIN (gabapentin) _
_Page 2 of 38_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance
10-2023
7.1 Special Populations, 7.1.1 Pregnant Women, Neonatal
withdrawal syndrome
02-2023
7.1 Special Populations, 7.1.1 Pregnant Women, Women of
childbearing potential/Contraception
10-2023
7.1 Special Populations, 7.1.1 Pregnant Women, Teratogenic
Potential
10-2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 4
4
DOSAGE AND ADMINISTRATION
......................
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Caracteristicilor produsului Caracteristicilor produsului franceză 16-10-2023

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor